Form 13-F position report

* NEUROCRINE BIOSCIENCES INC

Reported by ARMISTICE CAPITAL LLC

NBIX CUSIP 64125C109 Manager CIK 0001601086

Reported 565,251 shares, up 29,413 (5.5%) from the prior quarter.

Reported value -11.2%; share count 5.5% vs. the prior quarter.

Added
% of reported 13F value 0.98% This manager · Q3 2026
Shares 565,251 Quarter-end amount reported
Reported value $80,175,202 Fair value at quarter end
Consecutive quarters held 19 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-03-31 60938000
2022-06-30 129064000
2022-09-30 140622000
2022-12-31 107496000
2023-03-31 161142240
2023-06-30 155595000
2023-09-30 136841063
2023-12-31 138084480
2024-03-31 141194083
2024-06-30 134708443
2024-09-30 20898719
2024-12-31 121758000
2025-03-31 110621014
2025-06-30 84969457
2025-09-30 97847948
2025-12-31 116334639
2026-03-31 95379760
2026-06-30 90307457
2026-09-30 80175202

Quarterly position history

How this manager's reported quarter-end position changed over time.

19 quarters
Quarterly reported position history for * NEUROCRINE BIOSCIENCES INC held by ARMISTICE CAPITAL LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 565,251 +29,413 (5.5%) 0.98% $80,175,202 2026-11-16
Q2 2026 Reduced 535,838 -188,162 (-26.0%) 1.1% $90,307,457 2026-08-14
Q1 2026 Reduced 724,000 -96,240 (-11.7%) 1.7% $95,379,760 2026-05-15
Q4 2025 Added 820,240 +123,218 (17.7%) 1.38% $116,334,639 2026-02-17
Q3 2025 Added 697,022 +20,998 (3.1%) 1.45% $97,847,948 2025-11-17
Q2 2025 Reduced 676,024 -324,166 (-32.4%) 1.47% $84,969,457 2025-08-14
Q1 2025 Added 1,000,190 +108,190 (12.1%) 1.66% $110,621,014 2025-05-15
Q4 2024 Added 892,000 +710,619 (391.8%) 1.66% $121,758,000 2025-02-14
Q3 2024 Reduced 181,381 -797,107 (-81.5%) 0.33% $20,898,719 2024-11-14
Q2 2024 Reduced 978,488 -45,251 (-4.4%) 1.69% $134,708,443 2024-08-14
Q1 2024 Reduced 1,023,739 -24,261 (-2.3%) 1.87% $141,194,083 2024-05-15
Q4 2023 Reduced 1,048,000 -168,365 (-13.8%) 1.89% $138,084,480 2024-02-13
Q3 2023 Reduced 1,216,365 -433,635 (-26.3%) 2.1% $136,841,063 2023-11-14
Q2 2023 Added 1,650,000 +58,000 (3.6%) 2.25% $155,595,000 2023-08-14
Q1 2023 Added 1,592,000 +692,000 (76.9%) 2.32% $161,142,240 2023-05-15
Q4 2022 Reduced 900,000 -424,000 (-32.0%) 1.88% $107,496,000 2023-02-14
Q3 2022 Unchanged 1,324,000 0 (0.0%) 2.44% $140,622,000 2022-11-14
Q2 2022 Added 1,324,000 +674,000 (103.7%) 2.25% $129,064,000 2022-08-15
Q1 2022 New 650,000 +650,000 (0.0%) 1.18% $60,938,000 2022-05-16

Who else reported the position

876 managers reported * NEUROCRINE BIOSCIENCES INC for Q3 2026.

Managers reporting * NEUROCRINE BIOSCIENCES INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 14,856,103 +1,144,496 0.03% $2,107,189,670 9 qtrs
Dodge & Cox Reduced 5,504,578 -80,129 0.42% $780,769,344 13 qtrs
JPMorgan Chase & Co Reduced 5,292,589 -1,106,085 0.04% $733,010,216 48 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Added 5,060,036 +85,953 0.03% $717,715,506 3 qtrs
STATE STREET CORPORATION Added 4,807,975 +422,377 0.02% $681,963,174 54 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 4,580,803 +35,464 0.01% $649,741,098 3 qtrs
AQR CAPITAL MANAGEMENT LLC Reduced 3,062,385 -755,652 0.13% $422,547,761 35 qtrs
Vestal Point Capital LP Added 2,500,000 +620,000 9.16% $354,600,000 3 qtrs
RENAISSANCE TECHNOLOGIES LLC Reduced 2,300,697 -35,200 0.44% $326,330,862 32 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 2,127,482 -11,295 0.02% $301,038,376 54 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
565,251
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.